Preclinical, ZW1528
May 19, 2025
ATS
ZW1528, a Bispecific Antibody Targeting IL-4Rα and IL-33, Potently Inhibits Key Mediators of Airway Inflammation
Poffenberger et al.
Preclinical
April 30, 2025
AACR
ZW209, a DLL3 targeted trispecific T cell engager with integrated CD28 co-stimulation, demonstrates safety and potent preclinical efficacy in models of small cell lung cancer
Lau et al.
Preclinical
April 29, 2025
AACR
In vitro assays for prediction of ADC hematological toxicity: contribution of antibody, linker, and payload
Colombo et al.
Preclinical
April 28, 2025
AACR
ZW327, a novel Ly6E-targeting antibody-drug conjugate bearing a topoisomerase 1 inhibitor payload
Urosev et al.
Preclinical
April 28, 2025
AACR
Design and development of biparatopic antibody-drug conjugates against protein tyrosine kinase 7
Fung et al.
Preclinical
April 28, 2025
AACR
High throughput quantitative molecular characterization of cytotoxic antibody-drug conjugates in spheroid models for improved functional characterization, screening and candidate selection
Hogan et al.
Preclinical
April 23, 2025
Festival of Biologics
Trispecific T Cell Engagers Incorporating Conditional CD28 Co-Stimulation (TriTCE Co-Stim) to Improve Treatment Responses in Oncology
Chayne Piscitelli
Preclinical
January 29, 2025
Tumor Models Summit
TriTCE Co-Stim: A trispecific T cell engager platform with integrated CD28 co-stimulation to improve T cell function and anti-tumor responses in hard-to-treat cancers
Diana Canals Hernaez
Preclinical
January 29, 2025
Tumor Models Summit
Leveraging Humanized Mouse Models to Support T-Cell Engager Development
Nichole Escalante
Preclinical
January 15, 2025
PepTalk
Parallelization of Paratope Optimization and Antibody Format Screening for Efficient Characterization and Development of Multispecific T Cell Engagers
Meghan Verstraete
Preclinical, ZW171
November 9, 2024
SITC
Mechanistic QSP modeling and translational strategy for determining an FIH dose for ZW171, a bispecific 2+1 T-cell engager molecule targeting mesothelin and CD3
Charles Chen
Preclinical
November 5, 2024
PEGS
Azymetric Fc-based Therapeutic Modalities Enabling Tumor-Restricted Immune Cell Activation and Engagement
Thomas Spreter von Kreudenstein
